Literature DB >> 18484494

Comparison of the ability of various pharmaceutical silicates to amorphize and enhance dissolution of indomethacin upon co-grinding.

Deepak Bahl1, John Hudak, Robin H Bogner.   

Abstract

The physical stability, dissolution rate, and solubility enhancement of indomethacin amorphized by co-grinding with 6 pharmaceutical silicates were investigated. Mixtures of indomethacin and silicates were co-ground to amorphous states at room temperature and 75% relative humidity (RH) in a rolling jar mill. The fraction of indomethacin amorphized was higher than would be expected for monolayer coverage on the silicate, suggesting additional stabilization of the amorphous drug in the mesopores of the silicate. The co-ground amorphous indomethacin was physically stable for 3 to 6 months at 40 degrees C/75% RH. The physicochemical properties (surface area, crystallinity, presence and absence of metal ions such as Mg(2+), Al(3+), Ca(2+)) of the silicates affect the amorphization time, chemical stability, dissolution, and solubility.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18484494     DOI: 10.1080/10837450802012869

Source DB:  PubMed          Journal:  Pharm Dev Technol        ISSN: 1083-7450            Impact factor:   3.133


  3 in total

1.  Cogrinding as a tool to produce sustained release behavior for theophylline particles containing magnesium stearate.

Authors:  Ali Nokhodchi; Ononuju N Okwudarue; Hadi Valizadeh; Mohammad N Momin
Journal:  AAPS PharmSciTech       Date:  2009-10-28       Impact factor: 3.246

2.  Spontaneous crystalline-to-amorphous phase transformation of organic or medicinal compounds in the presence of porous media, part 3: effect of moisture.

Authors:  Ken K Qian; Dale E Wurster; Robin H Bogner
Journal:  Pharm Res       Date:  2012-03-20       Impact factor: 4.200

3.  Improvement in Dissolution Rate of Cefuroxime Axetil by using Poloxamer 188 and Neusilin US2.

Authors:  J Sruti; Ch N Patra; S K Swain; S Beg; H R Palatasingh; S C Dinda; M E Bhanoji Rao
Journal:  Indian J Pharm Sci       Date:  2013-01       Impact factor: 0.975

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.